Literature DB >> 28405553

Lyme Disease: A Case Report with Typical and Atypical Lesions.

Anuj Sharma1, Sandesh Guleria2, Reena Sharma1, Anita Sharma3.   

Abstract

Lyme disease is a multisystem infectious disease caused by the spirochete "Borrelia burgdorferi," which is transmitted by "Ixodes" tick, with skin being the most common and earliest organ to be affected. Diagnosis of erythema chronicum migrans (ECM), which is the characteristic lesion of early disease, may help in early treatment and prevention of complications. Here, we are reporting a case of Lyme disease in a 10-year-old young boy from a non-endemic zone of Himachal Pradesh, who presented with typical as well as atypical ECM lesions. The clinical diagnosis was confirmed serologically, and the child was treated successfully with doxycycline.

Entities:  

Keywords:  Atypical erythema chronicum migrans; Lyme disease; erythema chronicum migrans

Year:  2017        PMID: 28405553      PMCID: PMC5372433          DOI: 10.4103/2229-5178.202271

Source DB:  PubMed          Journal:  Indian Dermatol Online J        ISSN: 2229-5178


Introduction

Lyme disease is a multisystem illness caused by the strains of spirochete “Borrelia burgdorferi” which is transmitted by the various species of a tick named “Ixodes.”[1] The characteristic eruption, erythema chronicum migrans (ECM), at the site of inoculation is a common early manifestation, and dissemination of the infection may cause disease of the nervous system, heart, and joints, in addition to other dermatoses.[2] Although the disease has been mostly reported from temperate regions, the incidence has increased worldwide due to increasing travel and changing habitats of the vector. There are only a few previously reported cases from India.[3] This report illustrates a case of Lyme borreliosis in a young boy from Himachal Pradesh with classical ECM as well as atypical ECM lesions.

Case History

A 10-year-old boy from a hilly village presented in April 2016 with a 3-day history of sudden appearance of a painful brownish raised lesion over the back of his left leg, associated with surrounding redness which was increasing progressively. The child did not have fever or any other systemic complaints. He gave a history of visit to the nearby forest a few days before the appearance of the lesion. On examination, there was an erythematous annular plaque on the back of the left lower leg approximately 6 × 5 cm in size, with a central brownish fluid filled blister [Figure 1]. Induration and tenderness were present over the lesion, and local popliteal lymphadenopathy was seen. In addition, there was a lymphangitic streak on the inner aspect of the thigh [Figure 2a]. The patient also had petechiae over the scapular regions [Figure 2b] and a few maculopapular lesions over the dorsum of the hands and ankle region. Systemic examination was unremarkable. Clinical diagnosis of ECM was made.
Figure 1

Erythematous annular plaque measuring 6 × 5 cm in size with a central blister on the back of the left leg

Figure 2

Atypical erythema chronicum migrans (ECM) lesions; (a) ECM lesion with lymphangitic streak on the antero-medial aspect of the thigh, (b) atypical lesions in the form of petechiae on the right scapular area

Erythematous annular plaque measuring 6 × 5 cm in size with a central blister on the back of the left leg Atypical erythema chronicum migrans (ECM) lesions; (a) ECM lesion with lymphangitic streak on the antero-medial aspect of the thigh, (b) atypical lesions in the form of petechiae on the right scapular area The patient was subjected to baseline investigations including complete hemogram with peripheral blood smear which was found to be normal. Serology for Borrelia burgoderferi Ospc (23 KDa) antigen was done with enzyme-immunoassay technique. IgM was raised at 4.4 U/ml (normal <0.90), whereas IgG was found to be normal [0.3 U/ml (normal <0.90)], which was indicative of acute infection. Western blot could not be performed due to financial constraints. Biopsy from the active margin of the lesion showed moderate perivascular lymphocytic infiltrate with a focus of spongiosis, with papillary dermis showing extravasation of red blood cells [Figure 3].
Figure 3

Perivascular lymphocytic infiltrate with red blood cell extravasation into the papillary dermis (H and E, ×100)

Perivascular lymphocytic infiltrate with red blood cell extravasation into the papillary dermis (H and E, ×100) Treatment was initiated immediately with doxycycline 100 mg tablets twice daily along with other symptomatic therapy. After 1 week of treatment, the lesion did not progress beyond the initial size and there was a decrease in erythema and induration. At 2 weeks, there was further improvement in the above mentioned features associated with exfoliation of the skin [Figure 4a]. The medications were continued for a total of 3 weeks resulting in the clinical resolution of the lesion [Figure 4b].
Figure 4

(a) Improvement in erythema, disappearance of the advancing margin, and exfoliation after 2 weeks of treatment. (b) Resolution of the erythema chronicum migrans lesion and healing of the blister after 3 weeks

(a) Improvement in erythema, disappearance of the advancing margin, and exfoliation after 2 weeks of treatment. (b) Resolution of the erythema chronicum migrans lesion and healing of the blister after 3 weeks

Discussion

Lyme disease is caused by pathogenic genospecies of B. burgdorferi sensu lato (comprising at least 20 genospecies, both pathogenic and non-pathogenic): sensu stricto, afzelli, garinii, bavariensis, and speilmanni, of which B. garinni and B. afzelli have been most commonly implicated as pathogens in Asia (mainly central Asia).[3] Though the disease is most commonly found in temperate regions, it may exist in our country as the Ixodes ticks are said to be present in the Himalayan region. Various species of the genus Ixodes reported from this region are I. acutitarsus, I. granulatous, I. himalayensis, I. kashmericus, and I. ovatus.[4] The species of the tick said to be responsible for transmission of the disease in Asia is I. persulcatus (reported from central Asia) and has not been seen in India. Skin is the most commonly affected organ and the manifestations are called as “dermatoborreliosis.” The disease is divided into three stages, namely, early localized disease, disseminated disease, and chronic disease. ECM is seen in early localized disease and is widely regarded to be pathognomonic. It occurs at the site of a tick bite and can take two forms, i.e., either expansion with various hues of erythema or can spread centrifugally with central clearing and bull's eye, appearing like a target lesion. Atypical ECM lesions reported include vesicles, erythematous papules, purpura, and lymphangitic streaks. Differential diagnosis of ECM includes tinea corporis, urticaria, erythema multiforme, erythema annulare centrifugum, and fixed drug eruptions. Histopathology is characterized by the presence of a perivascular dermal lymphohistiocytic infiltrate with few interspersed plasma cells. Spirochetes may be demonstrated with Warthin-Starry stain in 50% of primary ECM lesions.[3] The diagnosis of ECM is mainly clinical with laboratory evidences acting as a supporting tool. Detection of B. burgdorferi by culture (expensive and lacks sensitivity) and/or polymerase chain reaction from skin biopsy are helpful in proving infection in suspected clinically atypical ECM manifestations. Serology has been the most practical and commonly used modality for the diagnosis of Lyme borreliosis; it is essential in all cases of clinically suspected Lyme borreliosis except ECM. It follows a two-step approach involving an initial screening test (usually ELISA) followed by a Western blot for reactive and equivocal samples. Single-step ELISA using recombinant proteins (such asC6 peptide) may replace the standard two-tiered strategy in the future.[5] Various antibiotics have been used with success for the treatment. Doxycycline (4 mg/kg/day in divided doses; maximum 200 mg/day; after 8 years of age) for 2 weeks is the drug of choice in early localized disease. Amoxycillin and cefuroxime axetil are equally effective alternatives. Disseminated disease usually requires parenteral treatment with ceftriaxone, cefotaxime, or benzyl penicillin.[6] Only few cases of Lyme disease have been reported from India in the past. A review of various cases/studies from the country is summarized in Table 1.[78910111213] The patient in the present case had both the characteristic centrifugally spreading lesion of ECM as well as other atypical lesions in the form of lymphangitic streaks, petechiae, and maculopapular lesions. This case report highlights the possibility of future risk of Lyme disease in Himachal Pradesh and warrants the treating physicians to be aware of its occurrence in this part of the world. Identifying the cutaneous features early can help in the prevention of development of advanced disease. Awareness needs to be created among the public regarding various preventive strategies.
Table 1

Review of cases/studies of Lyme's disease in India

Review of cases/studies of Lyme's disease in India

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  9 in total

1.  Lyme borreliosis: clinical case definitions for diagnosis and management in Europe.

Authors:  G Stanek; V Fingerle; K-P Hunfeld; B Jaulhac; R Kaiser; A Krause; W Kristoferitsch; S O'Connell; K Ornstein; F Strle; J Gray
Journal:  Clin Microbiol Infect       Date:  2011-01       Impact factor: 8.067

2.  A prospective study of Lyme arthritis in north India.

Authors:  R Handa; J P Wali; S Singh; P Aggarwal
Journal:  Indian J Med Res       Date:  1999-09       Impact factor: 2.375

3.  Seroprevalence of Borrelia burgdorferi in North Eastern India.

Authors:  A K Praharaj; S Jetley; A T Kalghatgi
Journal:  Med J Armed Forces India       Date:  2011-07-21

4.  Neuroretinitis as a manifestation of Lyme disease in South India: a case report.

Authors:  Kalpana Babu; Praveen R Murthy
Journal:  Ocul Immunol Inflamm       Date:  2010-04       Impact factor: 3.070

5.  Borrelial lymphocytoma cutis: a diagnostic dilemma.

Authors:  Rajat Kandhari; Sanjiv Kandhari; Sudhir Jain
Journal:  Indian J Dermatol       Date:  2014-11       Impact factor: 1.494

6.  Lyme disease in a Shimla boy.

Authors:  R K Patial; S Kashyap; S K Bansal; A Sood
Journal:  J Assoc Physicians India       Date:  1990-07

7.  Lyme disease in Haryana, India.

Authors:  Vijayeeta Jairath; Manu Sehrawat; Nidhi Jindal; V K Jain; Parul Aggarwal
Journal:  Indian J Dermatol Venereol Leprol       Date:  2014 Jul-Aug       Impact factor: 2.545

8.  Lyme borreliosis and skin.

Authors:  Biju Vasudevan; Manas Chatterjee
Journal:  Indian J Dermatol       Date:  2013-05       Impact factor: 1.494

Review 9.  Treatment of Lyme borreliosis.

Authors:  Hermann J Girschick; Henner Morbach; Dennis Tappe
Journal:  Arthritis Res Ther       Date:  2009-12-17       Impact factor: 5.156

  9 in total
  4 in total

1.  First report of Lyme disease in Nepal.

Authors:  Sher Bahadur Pun; Sumit Agrawal; Santoshananda Jha; Lila Nath Bhandari; Bimal Sharma Chalise; Abadhesh Mishra; Rajesh Shah
Journal:  JMM Case Rep       Date:  2018-01-10

2.  Commentary: Tick talk: A glimpse into the literature.

Authors:  Parthopratim Dutta Majumder
Journal:  Indian J Ophthalmol       Date:  2020-01       Impact factor: 1.848

3.  Seroprevalence of Lymes disease in the Nagarahole and Bandipur forest areas of South India.

Authors:  Kalpana Babu; Krishna R Murthy; M Bhagya; Praveen R Murthy; Vinuth N Puttamallesh; V Ravi
Journal:  Indian J Ophthalmol       Date:  2020-01       Impact factor: 1.848

4.  Non-malarial febrile illness: a systematic review of published aetiological studies and case reports from Southern Asia and South-eastern Asia, 1980-2015.

Authors:  Poojan Shrestha; Prabin Dahal; Chinwe Ogbonnaa-Njoku; Debashish Das; Kasia Stepniewska; Nigel V Thomas; Heidi Hopkins; John A Crump; David Bell; Paul N Newton; Elizabeth A Ashley; Philippe J Guérin
Journal:  BMC Med       Date:  2020-09-21       Impact factor: 8.775

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.